S&P 500

5.277,51

0,80%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Medicenna Therapeutics Corporation (MDNA)
Medicenna Therapeutics Corporation (MDNA) Notícias

MDNA

Medicenna Therapeutics (MDNA)

Medicenna Therapeutics Corporation

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:MDNA

1 2 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
14/05/2024	17:29	Edgar (US Regulatory)	Form 15-12G - Securities registration termination [Section 12(g)]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
14/05/2024	16:42	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:MDNA	Medicenna Therapeutics Corporation
13/05/2024	15:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
22/04/2024	17:40	Edgar (US Regulatory)	Form AW - Amendment Withdrawal Request	NASDAQ:MDNA	Medicenna Therapeutics Corporation
16/04/2024	18:05	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:MDNA	Medicenna Therapeutics Corporation
16/04/2024	18:05	Edgar (US Regulatory)	Form F-3/A - Registration statement by foreign private issuers: [Amend]	NASDAQ:MDNA	Medicenna Therapeutics Corporation
16/04/2024	18:04	Edgar (US Regulatory)	Form F-10POS - Post-effective amendment to a F-10EF registration	NASDAQ:MDNA	Medicenna Therapeutics Corporation
09/11/2023	10:56	GlobeNewswire Inc.	Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting	NASDAQ:MDNA	Medicenna Therapeutics Corporation
06/11/2023	09:00	GlobeNewswire Inc.	Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)	NASDAQ:MDNA	Medicenna Therapeutics Corporation
03/11/2023	13:00	GlobeNewswire Inc.	Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)	NASDAQ:MDNA	Medicenna Therapeutics Corporation
27/10/2023	08:55	GlobeNewswire Inc.	Medicenna Announces Nasdaq Delisting and Cutback of Management Team	NASDAQ:MDNA	Medicenna Therapeutics Corporation
25/10/2023	08:00	GlobeNewswire Inc.	Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors	NASDAQ:MDNA	Medicenna Therapeutics Corporation
24/10/2023	08:15	GlobeNewswire Inc.	Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)	NASDAQ:MDNA	Medicenna Therapeutics Corporation
10/10/2023	08:07	GlobeNewswire Inc.	Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer	NASDAQ:MDNA	Medicenna Therapeutics Corporation
03/10/2023	08:00	GlobeNewswire Inc.	Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy	NASDAQ:MDNA	Medicenna Therapeutics Corporation
28/09/2023	18:00	GlobeNewswire Inc.	Medicenna Announces Results of Annual and Special Meeting of Shareholders	NASDAQ:MDNA	Medicenna Therapeutics Corporation
28/09/2023	08:00	GlobeNewswire Inc.	Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy	NASDAQ:MDNA	Medicenna Therapeutics Corporation
06/09/2023	08:00	GlobeNewswire Inc.	Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:MDNA	Medicenna Therapeutics Corporation
28/08/2023	08:00	GlobeNewswire Inc.	Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer	NASDAQ:MDNA	Medicenna Therapeutics Corporation
14/08/2023	08:00	GlobeNewswire Inc.	Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management	NASDAQ:MDNA	Medicenna Therapeutics Corporation
08/08/2023	08:00	GlobeNewswire Inc.	Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee	NASDAQ:MDNA	Medicenna Therapeutics Corporation
04/08/2023	08:00	GlobeNewswire Inc.	Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023	NASDAQ:MDNA	Medicenna Therapeutics Corporation
01/08/2023	10:30	GlobeNewswire Inc.	Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology	NASDAQ:MDNA	Medicenna Therapeutics Corporation
28/07/2023	08:00	GlobeNewswire Inc.	Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights	NASDAQ:MDNA	Medicenna Therapeutics Corporation
25/07/2023	08:00	GlobeNewswire Inc.	Medicenna Presents at National Brain Tumor Society's Research Round Table	NASDAQ:MDNA	Medicenna Therapeutics Corporation
05/07/2023	08:00	GlobeNewswire Inc.	Medicenna Extends Period to Exercise Certain Warrants	NASDAQ:MDNA	Medicenna Therapeutics Corporation
27/06/2023	09:00	GlobeNewswire Inc.	Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights	NASDAQ:MDNA	Medicenna Therapeutics Corporation
27/04/2023	12:11	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:MDNA	Medicenna Therapeutics Corporation
27/04/2023	08:00	GlobeNewswire Inc.	Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement	NASDAQ:MDNA	Medicenna Therapeutics Corporation
18/04/2023	08:00	GlobeNewswire Inc.	Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference	NASDAQ:MDNA	Medicenna Therapeutics Corporation